Hepalys
Tokyo, Japan· Est.
A Japanese biopharma company developing lanifibranor, a pan-PPAR agonist for MASH, to address liver disease gaps in Asian patients.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A Japanese biopharma company developing lanifibranor, a pan-PPAR agonist for MASH, to address liver disease gaps in Asian patients.
HepatologyMetabolic Diseases
Technology Platform
Pan-PPAR agonist technology that simultaneously activates PPARα, δ, and γ isoforms to regulate metabolic, inflammatory, and fibrotic pathways in liver diseases.
Opportunities
Significant market opportunity in Japan and Asia where MASH prevalence is rising rapidly with limited treatment options, plus potential to expand pipeline through additional in-licensing of liver disease assets.
Risk Factors
Clinical risk of lanifibranor's Phase 3 data, competition from other late-stage MASH therapies (e.g., resmetirom), and regulatory challenges for first-in-class approval in Japan.
Competitive Landscape
Competes in crowded global MASH space with Madrigal's resmetirom (approved), 89bio's pegozafermin, and Akero's efruxifermin, but differentiates through Asian regional focus and pan-PPAR mechanism with potentially superior efficacy profile.